Florida Cancer Specialists & Research Achieves HITRUST i1 Certification to Manage Data Protection and Mitigate Cybersecurity Threats

HITRUST certification validates FCS is operating leading security practices to protect sensitive information.

FORT MYERS, Fla., Oct. 8, 2025 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS), a leading community oncology practice in Florida with nearly 100 locations, today announced that its Rx To Go pharmacy platforms and facility, as well as its Amazon Web Services, Centersquare Tampa Data Center and Google Cloud Platform GCP facilities have all earned certified status by HITRUST for information security.

HITRUST i1 Certification demonstrates that the practice's platforms and facilities are leveraging a set of curated controls to protect against current and emerging threats. The HITRUST i1 Validated Assessment and Certification helps organizations address cybersecurity challenges and remain cyber resilient over time.

"HITRUST i1 Certification gives our internal stakeholders confidence we are following leading security practices," said FCS Chief Technology Officer Trevor Heritage, PhD. "Practicing strong cybersecurity is critical to minimize information security risk and protect our organization and partners. The certification demonstrates our commitment to high standards for cybersecurity and data protection."

"The HITRUST i1 Validated Assessment is an important benchmark for cyber-aware organizations such as FCS," said Ryan Patrick, VP of Adoption at HITRUST. "Earning HITRUST i1 Certification reflects not only the effective implementation of information security controls, but also the organization's commitment to maintaining operational maturity across its cybersecurity program. We congratulate FCS on this significant achievement."

About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
For more than 40 years, Florida Cancer Specialists & Research Institute (FCS) has embraced innovation to deliver world-class care and drive the dramatic transformation of oncology care through its robust clinical research program.

FCS provides patients with access to a wide range of clinical trials, positioning it as a leader in research among private oncology practices in Florida and across the country. In fact, before receiving FDA approval, the majority of new cancer drugs in the U.S. were first made available to patients through participation in clinical trials at FCS.

Our outstanding team of highly trained and dedicated physicians is committed to delivering tailored treatment plans that make the best use of cutting-edge precision oncology advancements to enhance patient outcomes.

SOURCE Florida Cancer Specialists & Research Institute